Ingestible Sensors
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Infectious Vaccines Market Research Report 2024
1 Infectious Vaccines Market Overview
1.1 Product Overview and Scope of Infectious Vaccines
1.2 Infectious Vaccines Segment by Type
1.2.1 Global Infectious Vaccines Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 Infectious Vaccines Segment by Application
1.3.1 Global Infectious Vaccines Sales Comparison by Application: (2022-2028)
1.3.2 Adults
1.3.3 Pediatrics
1.4 Global Infectious Vaccines Market Size Estimates and Forecasts
1.4.1 Global Infectious Vaccines Revenue 2017-2028
1.4.2 Global Infectious Vaccines Sales 2017-2028
1.4.3 Infectious Vaccines Market Size by Region: 2017 Versus 2021 Versus 2028
2 Infectious Vaccines Market Competition by Manufacturers
2.1 Global Infectious Vaccines Sales Market Share by Manufacturers (2017-2022)
2.2 Global Infectious Vaccines Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Infectious Vaccines Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Infectious Vaccines Manufacturing Sites, Area Served, Product Type
2.5 Infectious Vaccines Market Competitive Situation and Trends
2.5.1 Infectious Vaccines Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Infectious Vaccines Players Market Share by Revenue
2.5.3 Global Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Infectious Vaccines Retrospective Market Scenario by Region
3.1 Global Infectious Vaccines Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Infectious Vaccines Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Infectious Vaccines Market Facts & Figures by Country
3.3.1 North America Infectious Vaccines Sales by Country
3.3.2 North America Infectious Vaccines Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Infectious Vaccines Market Facts & Figures by Country
3.4.1 Europe Infectious Vaccines Sales by Country
3.4.2 Europe Infectious Vaccines Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Infectious Vaccines Market Facts & Figures by Region
3.5.1 Asia Pacific Infectious Vaccines Sales by Region
3.5.2 Asia Pacific Infectious Vaccines Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Infectious Vaccines Market Facts & Figures by Country
3.6.1 Latin America Infectious Vaccines Sales by Country
3.6.2 Latin America Infectious Vaccines Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country
3.7.1 Middle East and Africa Infectious Vaccines Sales by Country
3.7.2 Middle East and Africa Infectious Vaccines Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Infectious Vaccines Historic Market Analysis by Type
4.1 Global Infectious Vaccines Sales Market Share by Type (2017-2022)
4.2 Global Infectious Vaccines Revenue Market Share by Type (2017-2022)
4.3 Global Infectious Vaccines Price by Type (2017-2022)
5 Global Infectious Vaccines Historic Market Analysis by Application
5.1 Global Infectious Vaccines Sales Market Share by Application (2017-2022)
5.2 Global Infectious Vaccines Revenue Market Share by Application (2017-2022)
5.3 Global Infectious Vaccines Price by Application (2017-2022)
6 Key Companies Profiled
6.1 CSL Limited (Australia)
6.1.1 CSL Limited (Australia) Corporation Information
6.1.2 CSL Limited (Australia) Description and Business Overview
6.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.1.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
6.1.5 CSL Limited (Australia) Recent Developments/Updates
6.2 Bavarian Nordic (Denmark)
6.2.1 Bavarian Nordic (Denmark) Corporation Information
6.2.2 Bavarian Nordic (Denmark) Description and Business Overview
6.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
6.2.5 Bavarian Nordic (Denmark) Recent Developments/Updates
6.3 GlaxoSmithKline plc. (U.K.)
6.3.1 GlaxoSmithKline plc. (U.K.) Corporation Information
6.3.2 GlaxoSmithKline plc. (U.K.) Description and Business Overview
6.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
6.3.5 GlaxoSmithKline plc. (U.K.) Recent Developments/Updates
6.4 Emergent Bio Solutions Inc. (U.S.)
6.4.1 Emergent Bio Solutions Inc. (U.S.) Corporation Information
6.4.2 Emergent Bio Solutions Inc. (U.S.) Description and Business Overview
6.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
6.4.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates
6.5 MedImmune LLC (U.S.)
6.5.1 MedImmune LLC (U.S.) Corporation Information
6.5.2 MedImmune LLC (U.S.) Description and Business Overview
6.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.5.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
6.5.5 MedImmune LLC (U.S.) Recent Developments/Updates
6.6 Johnson and Johnson (U.S.)
6.6.1 Johnson and Johnson (U.S.) Corporation Information
6.6.2 Johnson and Johnson (U.S.) Description and Business Overview
6.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
6.6.5 Johnson and Johnson (U.S.) Recent Developments/Updates
6.7 Novartis AG (Switzerland)
6.6.1 Novartis AG (Switzerland) Corporation Information
6.6.2 Novartis AG (Switzerland) Description and Business Overview
6.6.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
6.7.5 Novartis AG (Switzerland) Recent Developments/Updates
6.8 Merck and Company (U.S.)
6.8.1 Merck and Company (U.S.) Corporation Information
6.8.2 Merck and Company (U.S.) Description and Business Overview
6.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
6.8.5 Merck and Company (U.S.) Recent Developments/Updates
6.9 Sanofi Pasteur (France)
6.9.1 Sanofi Pasteur (France) Corporation Information
6.9.2 Sanofi Pasteur (France) Description and Business Overview
6.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
6.9.5 Sanofi Pasteur (France) Recent Developments/Updates
6.10 Pfizer Inc. (U.S.)
6.10.1 Pfizer Inc. (U.S.) Corporation Information
6.10.2 Pfizer Inc. (U.S.) Description and Business Overview
6.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
6.10.5 Pfizer Inc. (U.S.) Recent Developments/Updates
7 Infectious Vaccines Manufacturing Cost Analysis
7.1 Infectious Vaccines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Infectious Vaccines
7.4 Infectious Vaccines Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Infectious Vaccines Distributors List
8.3 Infectious Vaccines Customers
9 Infectious Vaccines Market Dynamics
9.1 Infectious Vaccines Industry Trends
9.2 Infectious Vaccines Market Drivers
9.3 Infectious Vaccines Market Challenges
9.4 Infectious Vaccines Market Restraints
10 Global Market Forecast
10.1 Infectious Vaccines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Infectious Vaccines by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Infectious Vaccines by Type (2023-2028)
10.2 Infectious Vaccines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Infectious Vaccines by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Infectious Vaccines by Application (2023-2028)
10.3 Infectious Vaccines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Infectious Vaccines by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Infectious Vaccines by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Infectious Vaccines Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Infectious Vaccines Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Infectious Vaccines Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Infectious Vaccines Market Competitive Situation by Manufacturers in 2021
Table 5. Global Infectious Vaccines Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Infectious Vaccines Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Infectious Vaccines Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Infectious Vaccines Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Infectious Vaccines Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Infectious Vaccines Manufacturing Sites and Area Served
Table 11. Manufacturers Infectious Vaccines Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Infectious Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infectious Vaccines as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Infectious Vaccines Sales by Region (2017-2022) & (K Units)
Table 16. Global Infectious Vaccines Sales Market Share by Region (2017-2022)
Table 17. Global Infectious Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Infectious Vaccines Revenue Market Share by Region (2017-2022)
Table 19. North America Infectious Vaccines Sales by Country (2017-2022) & (K Units)
Table 20. North America Infectious Vaccines Sales Market Share by Country (2017-2022)
Table 21. North America Infectious Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Infectious Vaccines Revenue Market Share by Country (2017-2022)
Table 23. Europe Infectious Vaccines Sales by Country (2017-2022) & (K Units)
Table 24. Europe Infectious Vaccines Sales Market Share by Country (2017-2022)
Table 25. Europe Infectious Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Infectious Vaccines Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Infectious Vaccines Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Infectious Vaccines Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Infectious Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Infectious Vaccines Revenue Market Share by Region (2017-2022)
Table 31. Latin America Infectious Vaccines Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Infectious Vaccines Sales Market Share by Country (2017-2022)
Table 33. Latin America Infectious Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Infectious Vaccines Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Infectious Vaccines Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Infectious Vaccines Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Infectious Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Infectious Vaccines Revenue Market Share by Country (2017-2022)
Table 39. Global Infectious Vaccines Sales by Type (2017-2022) & (K Units)
Table 40. Global Infectious Vaccines Sales Market Share by Type (2017-2022)
Table 41. Global Infectious Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Infectious Vaccines Revenue Share by Type (2017-2022)
Table 43. Global Infectious Vaccines Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Infectious Vaccines Sales (K Units) by Application (2017-2022)
Table 45. Global Infectious Vaccines Sales Market Share by Application (2017-2022)
Table 46. Global Infectious Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Infectious Vaccines Revenue Share by Application (2017-2022)
Table 48. Global Infectious Vaccines Price by Application (2017-2022) & (USD/Unit)
Table 49. CSL Limited (Australia) Corporation Information
Table 50. CSL Limited (Australia) Description and Business Overview
Table 51. CSL Limited (Australia) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. CSL Limited (Australia) Infectious Vaccines Product
Table 53. CSL Limited (Australia) Recent Developments/Updates
Table 54. Bavarian Nordic (Denmark) Corporation Information
Table 55. Bavarian Nordic (Denmark) Description and Business Overview
Table 56. Bavarian Nordic (Denmark) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Bavarian Nordic (Denmark) Infectious Vaccines Product
Table 58. Bavarian Nordic (Denmark) Recent Developments/Updates
Table 59. GlaxoSmithKline plc. (U.K.) Corporation Information
Table 60. GlaxoSmithKline plc. (U.K.) Description and Business Overview
Table 61. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product
Table 63. GlaxoSmithKline plc. (U.K.) Recent Developments/Updates
Table 64. Emergent Bio Solutions Inc. (U.S.) Corporation Information
Table 65. Emergent Bio Solutions Inc. (U.S.) Description and Business Overview
Table 66. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product
Table 68. Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates
Table 69. MedImmune LLC (U.S.) Corporation Information
Table 70. MedImmune LLC (U.S.) Description and Business Overview
Table 71. MedImmune LLC (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. MedImmune LLC (U.S.) Infectious Vaccines Product
Table 73. MedImmune LLC (U.S.) Recent Developments/Updates
Table 74. Johnson and Johnson (U.S.) Corporation Information
Table 75. Johnson and Johnson (U.S.) Description and Business Overview
Table 76. Johnson and Johnson (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Johnson and Johnson (U.S.) Infectious Vaccines Product
Table 78. Johnson and Johnson (U.S.) Recent Developments/Updates
Table 79. Novartis AG (Switzerland) Corporation Information
Table 80. Novartis AG (Switzerland) Description and Business Overview
Table 81. Novartis AG (Switzerland) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Novartis AG (Switzerland) Infectious Vaccines Product
Table 83. Novartis AG (Switzerland) Recent Developments/Updates
Table 84. Merck and Company (U.S.) Corporation Information
Table 85. Merck and Company (U.S.) Description and Business Overview
Table 86. Merck and Company (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Merck and Company (U.S.) Infectious Vaccines Product
Table 88. Merck and Company (U.S.) Recent Developments/Updates
Table 89. Sanofi Pasteur (France) Corporation Information
Table 90. Sanofi Pasteur (France) Description and Business Overview
Table 91. Sanofi Pasteur (France) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Sanofi Pasteur (France) Infectious Vaccines Product
Table 93. Sanofi Pasteur (France) Recent Developments/Updates
Table 94. Pfizer Inc. (U.S.) Corporation Information
Table 95. Pfizer Inc. (U.S.) Description and Business Overview
Table 96. Pfizer Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Pfizer Inc. (U.S.) Infectious Vaccines Product
Table 98. Pfizer Inc. (U.S.) Recent Developments/Updates
Table 99. Production Base and Market Concentration Rate of Raw Material
Table 100. Key Suppliers of Raw Materials
Table 101. Infectious Vaccines Distributors List
Table 102. Infectious Vaccines Customers List
Table 103. Infectious Vaccines Market Trends
Table 104. Infectious Vaccines Market Drivers
Table 105. Infectious Vaccines Market Challenges
Table 106. Infectious Vaccines Market Restraints
Table 107. Global Infectious Vaccines Sales Forecast by Type (2023-2028) & (K Units)
Table 108. Global Infectious Vaccines Sales Market Share Forecast by Type (2023-2028)
Table 109. Global Infectious Vaccines Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 110. Global Infectious Vaccines Revenue Market Share Forecast by Type (2023-2028)
Table 111. Global Infectious Vaccines Sales Forecast by Application (2023-2028) & (K Units)
Table 112. Global Infectious Vaccines Sales Market Share Forecast by Application (2023-2028)
Table 113. Global Infectious Vaccines Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 114. Global Infectious Vaccines Revenue Market Share Forecast by Application (2023-2028)
Table 115. Global Infectious Vaccines Sales Forecast by Region (2023-2028) & (K Units)
Table 116. Global Infectious Vaccines Sales Market Share Forecast by Region (2023-2028)
Table 117. Global Infectious Vaccines Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 118. Global Infectious Vaccines Revenue Market Share Forecast by Region (2023-2028)
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Infectious Vaccines
Figure 2. Global Infectious Vaccines Market Share by Type in 2021 & 2028
Figure 3. Preventive Vaccine Product Picture
Figure 4. Therapeutic Vaccine Product Picture
Figure 5. Global Infectious Vaccines Market Share by Application in 2021 & 2028
Figure 6. Adults
Figure 7. Pediatrics
Figure 8. Global Infectious Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Infectious Vaccines Market Size (2017-2028) & (US$ Million)
Figure 10. Global Infectious Vaccines Sales (2017-2028) & (K Units)
Figure 11. Infectious Vaccines Sales Share by Manufacturers in 2021
Figure 12. Global Infectious Vaccines Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Infectious Vaccines Players: Market Share by Revenue in 2021
Figure 14. Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Infectious Vaccines Sales Market Share by Region (2017-2022)
Figure 16. Global Infectious Vaccines Sales Market Share by Region in 2021
Figure 17. Global Infectious Vaccines Revenue Market Share by Region (2017-2022)
Figure 18. Global Infectious Vaccines Revenue Market Share by Region in 2021
Figure 19. U.S. Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Taiwan Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Philippines Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Vietnam Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. U.A.E Infectious Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Infectious Vaccines by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Infectious Vaccines
Figure 45. Manufacturing Process Analysis of Infectious Vaccines
Figure 46. Infectious Vaccines Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
CSL Limited (Australia) Bavarian Nordic (Denmark) GlaxoSmithKline plc. (U.K.) Emergent Bio Solutions Inc. (U.S.) MedImmune LLC (U.S.) Johnson and Johnson (U.S.) Novartis AG (Switzerland) Merck and Company (U.S.) Sanofi Pasteur (France) Pfizer Inc. (U.S.)